Completed PHASE1 INTERVENTIONAL 5-arm NCT02093923

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Sponsor: Shire

Conditions Hereditary Angioedema (HAE)

Interventions DX-2930 Placebo

Updated 8 times since 2017 Last updated: May 24, 2021 Started: May 14, 2014 Primary completion: May 18, 2015 Completion: May 18, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Hereditary Angioedema (HAE), this trial is completed. The trial is conducted by Shire and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amman, Jordan , Boston, United States , Chevy Chase, United States , Cincinnati, United States , Dallas, United States , Hershey, United States , Lake Oswego, United States , Milan, Italy , Mineola, United States , New York, United States and 4 more locations